Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms OrPHeUS
- Sponsors Actelion Pharmaceuticals
- 22 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Jun 2017 Planned initiation date changed from 30 Jun 2017 to 31 Jul 2017.
- 27 Jun 2017 New trial record